Desflurane Versus Propofol in the Sitting Position

NCT01436799 | Completed Results DMC

• 1 other identifier: GIRBA2466
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

The investigators hypothesized that both propofol and desflurane would decrease the regional oxygen saturation (rSO2) but propofol is likely to reduce rSO2 more than sevoflurane when patients are raised to the sitting position.

Conditions

Cerebral Ischemia

Keywords

propofol; desflurane; cerebrovascular circulation; sitting

Outcome Measures

Primary Outcomes (1)

• Regional Cerebral Oxygen Satuation (rSO2)

  definitive values of regional cerebral oxygen saturation(rSO2,%) values are described as mean (SD)

  1, 3, 5, 7, and 9 min after the beach chair position

Study Arms (2)

Desflurane

EXPERIMENTAL

anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane

Drug: Desflurane; Drug: alfentanil; Drug: Rocuronium

propofol

ACTIVE COMPARATOR

anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model

Drug: propofol; Drug: alfentanil; Drug: Rocuronium

Interventions

propofol DRUG

anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.

propofol

Desflurane DRUG

anaesthesia was maintained by desflurane 4-7vol%

Also known as: Des

Desflurane

alfentanil DRUG

administration of alfentanil 10 μg kg-1 for anesthetic induction

Also known as: alf

Desflurane; propofol

Rocuronium DRUG

administration of rocuronium 0.6 mg kg-1 for anesthetic induction

Also known as: roc

Desflurane; propofol

Eligibility Criteria

• Age: 20 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Forty patients,
• ASA class I or II,
• undergoing shoulder arthroscopy

You may not qualify if:

• Patients with history of cerebrovascular disease, coronary occlusive disease and/or obesity (body mass index \> 30) were excluded from this study.

Sponsors & Collaborators

• Gachon University Gil Medical Center: lead

MeSH Terms

Conditions

Brain Ischemia

Interventions

Propofol; Desflurane; Desmin; Alfentanil; GTF2A1L protein, human; Rocuronium; ROC Curve

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Ethyl Ethers; Ethers; Methyl Ethers; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Intermediate Filament Proteins; Biopolymers; Polymers; Macromolecular Substances; Cytoskeletal Proteins; Proteins; Amino Acids, Peptides, and Proteins; Fentanyl; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Androstanols; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Sensitivity and Specificity; Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Statistics as Topic; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Limitations and Caveats

limitations of this study is that the ventilation was adjusted according to ETCO2 value instead of the arterial carbon dioxide tensions (PaCO2).

Results Point of Contact

• Title: Dr.HJ Kwak
• Organization: Gachon University Gil Medical Center

hyun615@gilhospital.com

82-32-460-3400

Study Officials

• Hyun Jeong Kwak, MD.PhD

  Gachon University Gil Medical Center

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate professor

Study Record Dates

• First Submitted: September 15, 2011
• First Posted: September 20, 2011
• Study Start: March 1, 2011
• Primary Completion: August 1, 2011
• Study Completion: August 1, 2011
• Last Updated: September 9, 2013
• Results First Posted: August 26, 2013

Record last verified: 2013-08